CGT Group presents Coty Inc. with Most Innovative Company 2011 award
NEW YORK — The Consumer Goods Technology Group has awarded beauty company Coty Inc. with its Outstanding Achievement Award for Most Innovative Company for 2011.
The CGT Group, a group of senior leaders representing the consumer industry, unanimously awarded Coty with the achievement following a rigorous review of hundreds of entries. Three of Coty’s products were recognized as being the most innovative: Rimmel Lash Accelerator, for its Lash Growth Technology; Sally Hansen Salon Manicure, for the first encapsulation in nail lacquer; and Sally Hansen Special Effects, for its patented film technology.
The CGT Group’s board of directors — which includes executives from Alberto-Culver, Procter & Gamble, Unilever, Nestlé, Accenture, Miller-Coors, Gartner Group, DelMonte Foods and Rubbermaid — determined the recognition.
"Coty is thrilled to accept this prestigious honor," stated CEO Bernd Beetz. "We are humbled to be recognized by a board of peers who are industry giants in their respective companies. At the helm of this great company for 10 years now, I have seen first-hand the drive and creativity that embodies all those who work at Coty. I am confident that this achievement will propel us even further as we continue strengthening our innovation pipeline and delivering products that consumers love."
The award was presented recently to Coty and the company will be featured in the December publication of the Consumer Goods Technology Magazine.
Penn State Hershey Breast Center, Weis Markets partner on complementary mammogram initiative
HERSHEY, Pa. — Penn State Hershey Breast Center and Weis Markets on Thursday announced a new partnership with the Pennsylvania Department of Health’s HealthyWoman Program to provide mammograms to women in need.
“This partnership with Weis Markets and the HealthyWoman Program means we can help remove one of the barriers to women scheduling a potentially lifesaving mammogram,” stated Susann Schetter, division chief of breast imaging at Penn State Hershey Breast Center. “Because we know that early detection is the key to better outcomes for women diagnosed with breast cancer, we’re proud to be able to offer this service to those at most need in our community.”
“We are extremely pleased to be supporting a long-term program that offers prospect of detecting early cancers and benefits women with little or no insurance,” commented Dennis Curtin, Weis Markets’ director of public relations. “We hope our partnership with Penn State Hershey Breast Center results in improved access throughout Central Pennsylvania to the Pennsylvania Department of Health’s HealthyWoman Program.”
The Weis Markets Mammography Voucher Program will provide vouchers for free mammograms to uninsured or underinsured women in central Pennsylvania. The vouchers will be made available through the HealthyWoman Program, a Department of Health initiative that provides free breast and cervical cancer screening to women with low to moderate income.
The Department of Health’s HealthyWoman Program offers mammograms and Pap tests, preventive care and treatment to women with low to moderate income at no cost. Women between the ages of 40 years and 64 years and who have limited or no health insurance may be eligible.
DPP-IV inhibitors, GLP-1 analogues to see strongest growth among Type 2 diabetes drugs through 2020, study finds
BURLINGTON, Mass. — Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.
The study found that DPP-IV inhibitors and GLP-1 analogues would experience the biggest growth in market share among all drug classes, with a combined market share that will increase from 20% in 2010 to 47% in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The report found that Merck & Co.’s Januvia (sitagliptin) dominates DPP-IV drugs and will consolidate its position, while GLP-1 analogues will have a strong position as well, with Novo Nordisk’s Victoza (liraglutide) having the opportunity to edge up due to delays in the launch of Bydureon (exenatide), a once-weekly GLP-1 analogue made by Eli Lily & Co., Amylin Pharmaceuticals and Alkermes.